AbbVie (XSWX:ABBV) Accumulated Depreciation: CHF-6,521 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:ABBV AbbVie Inc XSWX:ABBV
76 GF Score
Price CHF211.45
GF Value CHF176.84
! 5 Warning Signs
View Full Analysis

What is AbbVie Accumulated Depreciation?

AbbVie XSWX:ABBV +0.67% 76 Accumulated Depreciation is CHF-6,521 Mil as of Jun. 2026. GuruFocus rates XSWX:ABBV with a GF Score™ of 76/100 and a GF Value™ of CHF176.84. The stock has 5 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

AbbVie's quarterly accumulated depreciation increased from Dec. 2025 (CHF-6,297 Mil) to Mar. 2026 (CHF-6,333 Mil) and increased from Mar. 2026 (CHF-6,333 Mil) to Jun. 2026 (CHF-6,521 Mil).

AbbVie's annual accumulated depreciation increased from Dec. 2023 (CHF-5,747 Mil) to Dec. 2024 (CHF-6,360 Mil) but then stayed the same from Dec. 2024 (CHF-6,360 Mil) to Dec. 2025 (CHF-6,297 Mil).

AbbVie Accumulated Depreciation Related Terms

AbbVie Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for AbbVie's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Accumulated Depreciation Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,173.26 -5,637.11 -5,747.46 -6,359.78 -6,297.10

AbbVie Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6,221.79 -6,166.59 -6,297.10 -6,333.04 -6,521.49
XSWX:ABBV
76GF Score
AbbVie Inc XSWX:ABBV
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of CHF-6,521 Mil mean?
AbbVie (XSWX:ABBV) has a Accumulated Depreciation of CHF-6,521 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on AbbVie and its competitors.
Is AbbVie's Accumulated Depreciation too high?
AbbVie's current Accumulated Depreciation is CHF-6,521 Mil. Overall, AbbVie has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Accumulated Depreciation compare to MRK and JNJ?
AbbVie's Accumulated Depreciation of CHF-6,521 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Drug Manufacturers company?
A good Accumulated Depreciation depends on the Drug Manufacturers industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on AbbVie and its competitors. AbbVie's current Accumulated Depreciation is CHF-6,521 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
AbbVie (XSWX:ABBV) has a current Accumulated Depreciation of CHF-6,521 Mil. The stock's GF Value™ is CHF176.84, compared to a current price of CHF211.45 — trading 19.6% above its estimated fair value. The current Accumulated Depreciation is CHF-6,521 Mil. AbbVie's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current Accumulated Depreciation is CHF-6,521 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (XSWX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of CHF211.45 is trading 19.6% above its estimated GF Value™ of CHF176.84.

Key valuation signals for XSWX:ABBV:

  • Accumulated Depreciation: CHF-6,521 Mil
  • GF Value™: CHF176.84 vs. price of CHF211.45 (19.6% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
76GF Score

Get the complete analysis for XSWX:ABBV

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF211.45
Price
CHF176.84
GF Value